Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 25;22(1):138.
doi: 10.3390/ijms22010138.

Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles

Asit Kumar  1 , Lina Zhou  1 , Kaining Zhi  2 , Babatunde Raji  2 , Shelby Pernell  1 , Erene Tadrous  1 , Sunitha Kodidela  1 , Anantha Nookala  3 , Harry Kochat  2 , Santosh Kumar  1
Affiliations
Review

Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles

Asit Kumar et al. Int J Mol Sci. .

Abstract

Biomaterials have been the subject of numerous studies to pursue potential therapeutic interventions for a wide variety of disorders and diseases. The physical and chemical properties of various materials have been explored to develop natural, synthetic, or semi-synthetic materials with distinct advantages for use as drug delivery systems for the central nervous system (CNS) and non-CNS diseases. In this review, an overview of popular biomaterials as drug delivery systems for neurogenerative diseases is provided, balancing the potential and challenges associated with the CNS drug delivery. As an effective drug delivery system, desired properties of biomaterials are discussed, addressing the persistent challenges such as targeted drug delivery, stimuli responsiveness, and controlled drug release in vivo. Finally, we discuss the prospects and limitations of incorporating extracellular vesicles (EVs) as a drug delivery system and their use for biocompatible, stable, and targeted delivery with limited immunogenicity, as well as their ability to be delivered via a non-invasive approach for the treatment of neurodegenerative diseases.

Keywords: biomaterial; drug delivery; drug loading; exosomes; extracellular vesicles; microvesicles/microparticles; neurodegenerative disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Possible advantages and disadvantages of biomaterials and extracellular vesicles as a drug delivery system.
See this image and copyright information in PMC

References

    1. Dugger B.N., Dickson D.W. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 2017;9 doi: 10.1101/cshperspect.a028035. - DOI - PMC - PubMed
    1. Jung Y.J., Tweedie D., Scerba M.T., Greig N.H. Neuroinflammation as a factor of neurodegenerative disease: Thalidomide analogs as treatments. Front. Cell Dev. Biol. 2019;7:313. doi: 10.3389/fcell.2019.00313. - DOI - PMC - PubMed
    1. Stephenson J., Nutma E., van der Valk P., Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018;154:204–219. doi: 10.1111/imm.12922. - DOI - PMC - PubMed
    1. Maher P. The potential of flavonoids for the treatment of neurodegenerative diseases. Int. J. Mol. Sci. 2019;20:3056. doi: 10.3390/ijms20123056. - DOI - PMC - PubMed
    1. Gong Y., Zhi K., Nagesh P.K.B., Sinha N., Chowdhury P., Chen H., Gorantla S., Yallapu M.M., Kumar S. An elvitegravir nanoformulation crosses the blood–brain barrier and suppresses HIV-1 replication in Microglia. Viruses. 2020;12:564. doi: 10.3390/v12050564. - DOI - PMC - PubMed

MeSH terms